{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T18:13:40Z","timestamp":1793902420952,"version":"4.8.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010376","name":"American Association of Clinical Endocrinologists","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019637","name":"Horizon Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019637","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.eprac.2022.06.003","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T13:01:36Z","timestamp":1655211696000},"page":"842-846","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Inflammatory and Noninflammatory Thyroid Eye Disease: Comparison of Disease Signs, Symptoms, and Quality of Life in Patients in the United States"],"prefix":"10.1016","volume":"28","author":[{"given":"Yao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4199-4844","authenticated-orcid":false,"given":"Lissa","family":"Padnick-Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Francis-Sedlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond S.","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.eprac.2022.06.003_bib1","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0002-9394(14)70276-4","article-title":"Clinical features of Graves' ophthalmopathy in an incidence cohort","volume":"121","author":"Bartley","year":"1996","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.eprac.2022.06.003_bib2","series-title":"Graves' Orbitopathy: A Multidisciplinary Approach - Questions and Answers","first-page":"1","article-title":"Clinical manifestations","author":"Dickinson","year":"2017"},{"issue":"4","key":"10.1016\/j.eprac.2022.06.003_bib3","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves\u2019 Orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2022.06.003_bib4","first-page":"113","article-title":"Ocular changes in Graves\u2019 disease. A long-term follow-up study","volume":"29","author":"Hales","year":"1960","journal-title":"Q\u00a0J Med"},{"issue":"10","key":"10.1016\/j.eprac.2022.06.003_bib5","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMcp0806317","article-title":"Clinical practice. Graves' ophthalmopathy","volume":"360","author":"Bartalena","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.eprac.2022.06.003_bib6","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0161-6420(96)30579-4","article-title":"Long-term follow-up of Graves ophthalmopathy in an incidence cohort","volume":"103","author":"Bartley","year":"1996","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.eprac.2022.06.003_bib7","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1038\/s41433-020-01297-w","article-title":"Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression","volume":"35","author":"Ugradar","year":"2021","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.eprac.2022.06.003_bib8","article-title":"Effects of teprotumumab on patients with long-standing, active thyroid eye disease","volume":"26","author":"Vinson","year":"2022","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"6","key":"10.1016\/j.eprac.2022.06.003_bib9","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/IOP.0000000000001942","article-title":"The \u201cQuiet TED\u201d-a special subgroup of thyroid eye disease","volume":"37","author":"I\u00f1iguez-Ariza","year":"2021","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"4","key":"10.1016\/j.eprac.2022.06.003_bib10","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1365-2265.2007.03087.x","article-title":"The impact of thyroid eye disease upon patients' wellbeing: a qualitative analysis","volume":"68","author":"Estcourt","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"10.1016\/j.eprac.2022.06.003_bib11","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1530\/EJE-11-0055","article-title":"Quality of life in thyroid eye disease: impact of quality of care","volume":"164","author":"Estcourt","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2022.06.003_bib12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1530\/EJE-07-0205","article-title":"Psychological implications of Graves' orbitopathy","volume":"157","author":"Coulter","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"10.1016\/j.eprac.2022.06.003_bib13","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1089\/thy.2017.0365","article-title":"Death by suicide in Graves' disease and Graves' orbitopathy: a nationwide Danish register study","volume":"27","author":"Ferlov-Schwensen","year":"2017","journal-title":"Thyroid"},{"issue":"4","key":"10.1016\/j.eprac.2022.06.003_bib14","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s40123-021-00385-8","article-title":"Quality of life in patients with chronic thyroid eye disease in the United States","volume":"10","author":"Cockerham","year":"2021","journal-title":"Ophthalmol Ther"},{"issue":"6","key":"10.1016\/j.eprac.2022.06.003_bib15","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1159\/000508071","article-title":"Predictive factors for changes in quality of life after steroid treatment for active moderate-to-severe Graves' orbitopathy: a prospective trial","volume":"9","author":"Hoppe","year":"2021","journal-title":"Eur Thyroid J"},{"issue":"6","key":"10.1016\/j.eprac.2022.06.003_bib16","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S2213-8587(21)00056-5","article-title":"Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials","volume":"9","author":"Kahaly","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.eprac.2022.06.003_bib17","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1530\/eje.0.1460751","article-title":"Long-term effects of Graves' ophthalmopathy on health-related quality of life","volume":"146","author":"Terwee","year":"2002","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.eprac.2022.06.003_bib18","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000477803","article-title":"Does Graves' orbitopathy ever disappear? Answers to an old question","volume":"6","author":"Sabini","year":"2017","journal-title":"Eur Thyroid J"},{"key":"10.1016\/j.eprac.2022.06.003_bib20","series-title":"Symptoms of generalized anxiety disorder among adults: United States, 2019. NCHS Data Brief, no 378","author":"Terlizzi","year":"2020"},{"issue":"8","key":"10.1016\/j.eprac.2022.06.003_bib22","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1167\/iovs.13-13704","article-title":"Changes of lacrimal gland and tear inflammatory cytokines in thyroid-associated ophthalmopathy","volume":"55","author":"Huang","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"10.1016\/j.eprac.2022.06.003_bib23","doi-asserted-by":"crossref","first-page":"e800","DOI":"10.1111\/aos.14000","article-title":"Dry eye syndrome in thyroid eye disease patients: the role of increased incomplete blinking and Meibomian gland loss","volume":"97","author":"Park","year":"2019","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"10.1016\/j.eprac.2022.06.003_bib24","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12886-018-0763-9","article-title":"The function and morphology of Meibomian glands in patients with thyroid eye disease: a preliminary study","volume":"18","author":"Wang","year":"2018","journal-title":"BMC Ophthalmol"},{"issue":"9","key":"10.1016\/j.eprac.2022.06.003_bib25","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1023\/A:1016647407161","article-title":"Perception of quality of life by patients, partners and treating physicians","volume":"9","author":"Wilson","year":"2000","journal-title":"Qual Life Res"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X22005365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X22005365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:13:41Z","timestamp":1761516821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X22005365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1530891X22005365"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2022.06.003","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inflammatory and Noninflammatory Thyroid Eye Disease: Comparison of Disease Signs, Symptoms, and Quality of Life in Patients in the United States","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2022.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 AACE. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}